Donate to our Cause


Browse the latest video presentations on topics such as cancer, heart disease, and oxidative stress from Randolph M. Howes, M.D., Ph.D.

View our Videos ›


Download the latest books from The Howes Selective World Library of Oxygen Metabolism. Dr. Howes currently has 11 books in publication.

Browse the Online Store ›


Archive for the ‘About’ Category

Mission & Values

Nov 30, 2010

Quality • Speed • Passion

At U.S. Medical Scientific Research Foundation, our core values are what we stand for, what we prize, what we seek in people we hire, and what we demand from each other. They are:

  • Quality of scientific investigations
  • Speed of execution
  • Passion for improving the lives of patients and disease prevention

As a science-driven business, our success depends on maintaining the highest standards of quality in realizing the potential of our products to benefit patients. Our focus on the highest standards of quality extends to all the work we do.
As a fierce competitor in an intensely competitive industry, our success depends on our ability to execute quickly and effectively – to set, meet, and exceed aggressive milestones and goals. Patients desperately need our drugs, once their safety has been established.

And finally, as people who are in this industry and at this organization to make a difference, we are united by our desire to improve the lives of severely ill patients and to prevent others from getting these diseases. Disease prevention is also a major goal.

Our core values shape who we are today and the organization we will become in the years ahead.


The U.S. Medical Scientific Research Foundation mission is to cure and prevent disease and to extend and enhance the lives of patients by discovering, developing, and commercializing breakthrough products for severe medical conditions. Our goal is to create a national medical research organization that is a center for scientific and operational excellence.

While our strategy, our plan for achieving our mission, must be flexible enough to adapt to new results from our research or changes in the marketplace, the core beliefs expressed in our guiding principles do not change. These principles reflect our values and underlie how we treat each other and the judgment each of us must show in the choices we face every day. They are the key to the long-term success of U.S. Medical Scientific Research Foundation.

We believe that following these principles will lead to better lives for our patients and rewarding careers for our future employees.

All of us will succeed if we maintain integrity, passion and creativity, which is based on solid scientific data.


Nov 30, 2010

At U.S. Medical Scientific Research Foundation, our strategy is to use our developmental compound library and strength in discovery and development to discover, and commercialize new drugs for severe medical conditions.

We believe U.S. Medical Scientific Research Foundation has a number of critical assets and capabilities that support our strategy and provide competitive advantages:

• Our unique biochemical compound library, the source of each of our pipeline drug candidates

• Our experience in innovative drug discovery that will lead to the discovery of first-in-class and best-  in-class compound families

• Our capabilities in development, evidenced by our track record in designing, implementing, and conducting clinical trials and laboratory studies with EMODs

• Our focus on small-molecule drugs (EMODs), which have substantial advantages in patient convenience, safety and operating margins over injectable pharmaceutical drugs
We will continue to build on these strengths as we pursue our mission to extend and enhance the lives of severely ill patients. Disease prevention is equally important with disease control and cure.


To date U.S. Medical Scientific Research Foundation has maintained all rights to all of our products in all markets and indications. Going forward, partnerships with other pharmaceutical and medical device companies may play an important role in our growth. We expect to regularly evaluate partnership opportunities that enhance the overall value of our programs through a combination of complementary products or technologies, financial commitment, and commercial capabilities.
In addition to evaluating select strategic corporate partnership opportunities, we will strive to access leading-edge scientific R & D through our collaborations with researchers at top-tier academic institutions. U.S. Medical Scientific Research Foundation has formed numerous such alliances, and seeks outstanding collaborators for advancing the scientific understanding of our products and disease targets.


U.S. Medical Scientific Research Foundation places the utmost importance on protecting its intellectual assets and maintains a potential portfolio of domestic and foreign patents and patent applications.
Our patent estate currently is in the developmental phase, including compositions of matter, syntheses, and methods of use in the fields of cancer and autoimmune disease, as well as in other therapeutic areas within the organization’s focus. We will pursue exclusive licenses to several families of patent filings.
Our lead products are new chemical and biochemical entities that are structurally unique and will be well protected by composition of matter and method claims. Our intellectual property portfolio contains potential patent filings on novel excited state molecules and their targets and novel methods of utilization.

Our Donors

Nov 23, 2010

Content coming soon.

Board Members

Nov 22, 2010

Randolph M. Howes, M.D., Ph.D., Director

Robert J. Muller, M.D., Board Member

Robert C. Allen, M.D., Board Member

Paul Manson, M.D., Board Member

Richard Steele, Ph.D., Board Member

Michael R. Root, M.S., Board Member

Our History

Nov 22, 2010

U.S. Medical Scientific Research Foundation may need a joint venture with a company to discover and develop novel drug candidates. This joint venture, structured as a majority-owned U.S.-based subsidiary of U.S. Medical Scientific Research Foundation parent company, could bring together two essential elements for successful drug discovery: the scale, financial commitment, and chemistry expertise of the corporate partner; and the biochemical expertise of the founder’s, leading scientist, Dr. Randolph Howes.

U.S. Medical Scientific Research Foundation does not resemble a traditional biotechnology company, which is often founded based on one particular technology or product and may have a limited spectrum of pharmaceutical development capabilities. As a result, U.S. Medical Scientific Research Foundation has a diversified pipeline of potential drug candidates, and the full set of capabilities necessary to develop products from target identification through lead optimization, preclinical development, and clinical trials.

Our unique history has allowed us to combine the high-energy culture and exciting growth opportunities of a new biotechnology research organization, with the drug development assets and expertise of a mature scientific and pharmaceutical organization.


Nov 21, 2010

Internationally, especially in under developed third world countries, the major killers are malaria and HIV/AIDS; whereas, in developed countries, such as the United States of America, the major fatal diseases are related to cancer and cardiovascular system, such as atherosclerosis, myocardial infarction and strokes. President Nixon declared war on cancer in 1971 and we have made only marginal advances in the cure and prevention of most forms of neoplasia. Cardiovascular diseases are currently at epidemic proportions and, even though we have established long lists of risk factors, these diseases continue to plague our population in all families, communities and states.

Our theories on cancer, which is not a singular disease entity, vary with the source of causation, i.e., chemical mutagens or pollutants, viruses, irradiation, smoking, etc., and our means of prevention is limited to the marginally effective attempts to stop tobacco use and possible avoidance of toxins and radiation. In short, we desperately need innovative and creative insights into effective, new methods of treatment of established diseases and extrapolation of solid scientifically based principles for disease prevention. I have dedicated my life to the eradication of these diseases and to the development of safe, cost effective and readily available means of disease cure, reversal and prevention.

My theories are based on my in-depth knowledge of oxygen metabolism, especially as it relates to electronically modified oxygen derivatives (EMODs), such as the superoxide anion, hydrogen peroxide, hypochlorous acid, peroxynitrite and electronically excited singlet molecular oxygen. I have written voluminous referenced tomes, based on peer reviewed articles, on these subjects, available at www.thepundit.com, and have applied my methods in limited pilot studies to establish a proof of principle. One such study, performed at Tuft’s Medical School, showed a 22% cure rate of human squamous cell carcinoma, which had been implanted into athymic mice and with a 40% reduction in growth rate of other cancer groups. My studies on micro-injections of singlet oxygen generating systems into human basal cell skin cancers produced over an 80% cure rate, with only single injections. My singlet oxygen generating systems use only physiologically available EMODs, which are present (orthomolecular) in steady state levels in all aerobic cells in humans at all times. This alone, emphasizes their low toxicity and unlimited therapeutic potential.

The major difficulty facing my system has been the half a century indoctrination of the invalidated free radical theory of Denham Harman. The free radical theory fails to meet the criteria of the scientific method and is nullified by its repeated lack of predictability for the use of antioxidant vitamins in over one million human subjects, which I have reviewed. The free radical theory was negated by randomized, double blind, clinical trials and meta-analysis, which is the scientific gold standard. Yet, after 50 years, world orthodoxy clings to its myths and half-truths regarding the benefits of antioxidants and the alleged damage of prooxidants, such as EMODs. My extensive writings substantiate my position that EMODs are of low toxicity, if any, and are crucial for pathogen and neoplasia protection.

In order to maintain a state of healthy homeostasis, our body’s immune system and our defensive white blood cells (WBCs) utilize EMODs to hold in abeyance and to kill bacteria, viruses (HIV/AIDs), protozoans (malaria), fungi (Candida) and to induce cellular suicide (apoptosis) in newly forming cancerous cells. Antioxidants, such as vitamin E, C and beta carotene, have been shown to block the killing of cancer cells by EMODs and this has grave implications for patients with cancerous or precancerous conditions.

Only if I can follow the stepwise tradition of laboratory experimentation leading ultimately up to clinical trials, can I bring my methods to the patient’s bedside. It is in that regard that I wish to establish a foundation, whereby I can make these dreams of disease and pain prevention a reality. The steadfast, wide-spread sycophants of the discredited free radical theory make it a near impossibility to utilize traditional methods of funding. Thus, with delight, I am prepared to fund these research endeavors. It is my dream to have my methods preventing and curing these dreaded diseases at the patient’s bedside in my life time. My foundation will represent one more positive step in that direction.

Funds will be utilized for studies at accredited institutions, such as Johns Hopkins Hospital in Baltimore, Md. and/or Southeastern Louisiana University in Hammond, La. and at approved laboratories, such as Charles Rivers in Boston, Mass. Initially, experiments will utilize normal and cancerous cell culture techniques for tumoricidal activity, viral cultures to evaluate virucidal oxidative systems and bacterial or protozoan specimens to determine bactericidal and malarial killing properties. Later experiments will involve the use of standard experimental laboratory animals and the final stages will move, with appropriate governmental approval, to clinical testing. I have estimated a ten year interval to get to the clinical stage of these investigations.

The impact of these potentially successful studies could lead to the prevention of many forms of cancer and preventative methods for increasing an individual’s oxidative capacity to oxidize plasma micro-aggregates for excretion and arteriosclerotic plaque prevention. Successful bactericidal studies could lead to cures for sepsis and subsequent death. Methods to eliminate the scourges of malaria and HIV/AIDS could have unlimited potential for the currently 40 million HIV patients and for the millions affected by malaria annually. This work must go forward and I am willing to utilize my personal funds for the greater good of mankind.

About Us

U.S. Medical Scientific Research Foundation is a bio-scientific company focused on discovering, developing, and commercializing products (chemicals and/or devices) for extending and enhancing the lives of patients with severe medical conditions, such as cancer, atherosclerosis, malaria, obesity, diabetes, arthritis and HIV/AIDS. Our secondary goal is to develop methods of disease prevention utilizing exclusive knowledge of oxygen metabolism. We have novel, small-molecular and orthomolecular drug candidates, which are designed to target major unmet needs in large therapeutic markets, including cardiovascular disease, diabetes, chronic inflammatory diseases, such as arthritis and all forms of cancer. All potential commercial products will be developed internally, and we fully own all rights in all indications and markets.

U.S. Medical Scientific Research Foundation: huge corporate potential, small company speed:

• Diverse potential: U.S. Medical Scientific Research Foundation has a multi-product portfolio with each program representing a distinct biochemical family, mechanism of action, and therapeutic category. This profile distinguishes the products, regulatory, and market risks of our pipeline, while still capturing the synergies of one central theme driving discovery and development.

• Category-leading potential: Our products target major unmet needs in large therapeutic markets, especially cancer, cardiovascular disease, malaria and HIV/AIDS. These compounds have the potential to establish major new therapeutic franchises. We believe our first-mover advantages, proprietary knowledge, strong intellectual property position, and fully-integrated discovery engine increase our competitive advantage within the franchise. Our goal is to be best-in-class in addition to first-in-class.

• Small-molecule focus: Small-molecule drug candidates require lower investment in infrastructure, face fewer manufacturing constraints, and have lower ongoing costs than biologic drugs. Small-molecule drugs and tailored orthomolecular drugs also present advantages to patients and providers: they may be developed as orally active drugs, offering patients more convenient drug administration and storage than injectable drugs, as well as extended drug stability. Additionally, injectable drugs and inhalable drugs are in the pipeline. Electronically modified oxygen derivatives (EMODs) are central to our research and development.

• High productivity discovery engine with unique chemical library: U.S. Medical Scientific Research Foundation owns a compound and supplement library with orthomolecular drug-like compounds assembled from non-traditional, non-combinatorial sources. All current clinical candidates were discovered and developed internally by the U.S. Medical Scientific Research Foundation R&D team, led by Randolph M. Howes M.D., Ph.D.

U.S. Medical Scientific Research Foundation combines the high-energy culture and exciting growth opportunities of a new biotechnology company with the drug development assets and expertise of a mature pharmaceutical organization. Development of associated medical devices is a natural outgrowth of research with our products.